Boston Scientific (BSX) Expected to Announce Quarterly Earnings on Wednesday

Boston Scientific (NYSE:BSX) will likely be posting its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect the company to announce earnings of $0.78 per share and revenue of $5.2896 billion for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 8:00 AM ET.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $91.83 on Tuesday. The firm has a 50 day moving average of $95.08 and a 200 day moving average of $99.38. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $136.13 billion, a price-to-earnings ratio of 49.11, a price-to-earnings-growth ratio of 1.66 and a beta of 0.67. Boston Scientific has a 52 week low of $85.98 and a 52 week high of $109.50.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Morgan Stanley upped their price objective on Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Royal Bank Of Canada increased their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Citigroup restated a “buy” rating on shares of Boston Scientific in a report on Wednesday, January 14th. Evercore ISI set a $112.00 price objective on shares of Boston Scientific in a research note on Monday, January 5th. Finally, National Bankshares set a $115.00 target price on shares of Boston Scientific in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $123.89.

Insider Buying and Selling

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. The trade was a 34.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is owned by company insiders.

Institutional Trading of Boston Scientific

Several large investors have recently added to or reduced their stakes in BSX. Northern Trust Corp increased its holdings in shares of Boston Scientific by 0.9% in the third quarter. Northern Trust Corp now owns 14,402,636 shares of the medical equipment provider’s stock valued at $1,406,129,000 after purchasing an additional 128,188 shares during the period. Amundi boosted its position in Boston Scientific by 17.5% in the third quarter. Amundi now owns 11,981,584 shares of the medical equipment provider’s stock valued at $1,158,619,000 after buying an additional 1,781,830 shares during the last quarter. Marshall Wace LLP boosted its position in Boston Scientific by 30.7% in the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock valued at $956,680,000 after buying an additional 2,301,383 shares during the last quarter. Lazard Asset Management LLC increased its holdings in Boston Scientific by 1.3% in the 3rd quarter. Lazard Asset Management LLC now owns 6,719,769 shares of the medical equipment provider’s stock worth $656,051,000 after buying an additional 87,009 shares during the period. Finally, Man Group plc raised its position in Boston Scientific by 79.8% during the 3rd quarter. Man Group plc now owns 3,843,937 shares of the medical equipment provider’s stock worth $375,284,000 after buying an additional 1,706,494 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.